Mr. Ibrahem/Telotristat
Clinical data
Trade namesXermelo
Other namesTelotristat ethyl, LX1032, LX1606
AHFS/Drugs.comMonograph
MedlinePlusa617029
License data
Pregnancy
category
  • AU: B3
Routes of
administration
By mouth (tablets)
Legal status
Legal status
Pharmacokinetic data
Protein binding>99% (both telotristat ethyl and telotristat)
MetabolismHydrolysis via carboxylesterases
MetabolitesTelotristat
Elimination half-life0.6 hours (telotristat ethyl), 5 hours (telotristat)
ExcretionFeces (92.8%), urine (less than 0.4%)[1]
Identifiers
  • [(S)-Ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate]
Chemical and physical data
FormulaC27H26ClF3N6O3
Molar mass574.99 g·mol−1
3D model (JSmol)
  • CCOC(=O)C(CC1=CC=C(C=C1)C2=CC(=NC(=N2)N)OC(C3=C(C=C(C=C3)Cl)N4C=CC(=N4)C)C(F)(F)F)N
  • InChI=1S/C27H26ClF3N6O3/c1-3-39-25(38)20(32)12-16-4-6-17(7-5-16)21-14-23(35-26(33)34-21)40-24(27(29,30)31)19-9-8-18(28)13-22(19)37-11-10-15(2)36-37/h4-11,13-14,20,24H,3,12,32H2,1-2H3,(H2,33,34,35)/t20-,24+/m0/s1
  • Key:MDSQOJYHHZBZKA-GBXCKJPGSA-N

Telotristat, sold under the brand name Xermelo, is a medication used to treat diarrhea due to carcinoid syndrome.[3] It is taken by mouth, three times per day.[3] It is used together with a somatostatin like agent.[3]

Common side effects include abdominal pain, liver problems, and tiredness.[2] Other side effects may include constipation.[3] Smaller doses may be required in those with liver problems.[2] Use during pregnancy is not recommended.[4] It works by blocking tryptophan hydroxylase, thereby decreasing the production of serotonin.[3][2]

Telotristat was approved for medical use in the United States and Europe in 2017.[3][2] In the United States it costs about 8,000 USD per month as of 2021.[5] This amount in the United Kingdom costs the NHS about £1,100.[4]

References

edit
  1. ^ a b "Xermelo- telotristat ethyl tablet". DailyMed. 30 October 2020. Archived from the original on 12 November 2020. Retrieved 11 November 2020.
  2. ^ a b c d e f "Xermelo EPAR". European Medicines Agency (EMA). Archived from the original on 29 December 2019. Retrieved 17 April 2020.
  3. ^ a b c d e f g h "Telotristat Monograph for Professionals". Drugs.com. Archived from the original on 5 March 2021. Retrieved 25 September 2021.
  4. ^ a b BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 938. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  5. ^ "Xermelo Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 11 July 2021. Retrieved 25 September 2021.